Indivior Pharmaceuticals Inc

NASDAQ:INDV

Drug Manufacturers - Specialty & Generic

Healthcare
$36.28 +0.69%

+$0.26 today

Market cap
$4.53B
Beta
1.17
P/E (TTM)
19.1
EPS (TTM)
$2.00
52W Low $13.45High $41.00

Volume 3.65M

Average 2.08M

INDV Interest Expense

Cost of servicing the company's debt during the period.

Indivior Pharmaceuticals IncNASDAQ: INDV

Interest Expense · Q2 FY2026 · quarter ended Jun 2026

Interest expense declines year over year

Q2 FY2026 interest expense of $2M fell 86.7% year over year, behind the -46.0% change in trailing-twelve-month interest expense. Sequentially, it fell 71.4% from the prior quarter. Over 3 fiscal years it compounded at +15.8% a year.

Context

  • Interest expense amounted to 3.6% of revenue in FY2025, up 0.2 pp from a year earlier.
  • Interest expense increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -86.7% toward the trailing-twelve-month pace of -46.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$2M-71.4% QoQ
Last fiscal yearDec 2025
$45M+9.8% YoY
LTMJun 2026
$27M-46.0% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-86.7%——
1 year+9.8%——
3-year CAGR+15.8%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
45M USD
Year-over-year change
+9.8%
4-year CAGR
+14.7%

Interest Expense vs competitors

How INDV compares with its peers on the latest reported figures

  • INDV's LTM Jun 2026 interest expense of $27M is the 3rd highest of the 4 companies compared; the peer median is $86.65M.
  • Its year-over-year change of -46.0% is the lowest of 3, against a peer median of +937.3%.
  • Interest expense amounts to 2.0% of revenue for INDV, versus a peer median of 4.9%.
INDV Competitors Peer median
Interest Expense for INDV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$162.89M +110.4%+9.2%20.5%
ALKSAlkermes plcLTM Sep 2026$86.65M +1764.1%-2.0%4.9%
INDVIndivior Pharmaceuticals IncLTM Jun 2026$27M -46.0%+15.8%2.0%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$2.32M ——0.3%
Peer median (excluding INDV) $86.65M+937.3%+3.6%4.9%

Competitors are the stored peer set for INDV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue791M901M1.09B1.19B1.24B
Cost of Revenue127M151M174M231M246M
Gross Profit664M750M919M957M993M
Gross Margin83.9%83.2%84.1%80.6%80.1%
Research & Development52M74M116M107M97M
Selling, General & Admin431M469M569M618M634M
Operating Expenses451M831M1.08B925M728M
Depreciation & Amortization22M16M15M28M20M
EBITDA238M(46M)(99M)83M304M
EBITDA Margin30.1%-5.1%-9.1%7.0%24.5%
Operating Income213M(81M)(156M)32M265M
Operating Margin26.9%-9.0%-14.3%2.7%21.4%
Interest Income4M19M43M23M22M
Interest Expense26M29M35M41M45M
Other Income / Expenses(23M)(8M)7M(18M)(26M)
Income Before Tax190M(89M)(149M)14M239M
Pre-Tax Margin24.0%-9.9%-13.6%1.2%19.3%
Income Tax Expense(15M)(44M)(20M)11M29M
Net Income205M(44M)(129M)2M210M
Net Margin25.9%-4.9%-11.8%0.2%16.9%
EPS (Basic)1.38(0.37)(0.94)0.021.68
EPS (Diluted)1.31(0.37)(0.91)0.021.64
Weighted Avg Shares145.66M139.01M137.31M132M125M
Weighted Avg Shares (Diluted)154.23M139.01M141.8M133M128M

Indivior Pharmaceuticals Inc

NASDAQ:INDV

Intrinsic Alpha fair value

Locked

Current Price

$36.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.